Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

  • Torres Esquius, Sara
  • Feliubadaló, Lídia
  • Moreno-Cabrera, José Marcos
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Rofes, Paula
  • del Valle, Jesús
  • Stradella, Agostina
BARD1; Càncer hereditari de mama i ovari; Risc moderat de càncer, BARD1; Cáncer de mama y ovario hereditario; Riesgo de cáncer moderado, BARD1; Hereditary breast and ovarian cancer; Moderate cancer risk, Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1-associated ring domain 1 (BARD1), nuclear partner of BRCA1, has been suggested as a potential HBOC risk gene, although its prevalence and penetrance are variable according to populations and type of tumor. We aimed to investigate the prevalence of BARD1 truncating variants in a cohort of patients with clinical suspicion of HBOC. A comprehensive BARD1 screening by multigene panel analysis was performed in 4015 unrelated patients according to our regional guidelines for genetic testing in hereditary cancer. In addition, 51,202 Genome Aggregation Database (gnomAD) non-Finnish, non-cancer European individuals were used as a control population. In our patient cohort, we identified 19 patients with heterozygous BARD1 truncating variants (0.47%), whereas the frequency observed in the gnomAD controls was 0.12%. We found a statistically significant association of truncating BARD1 variants with overall risk (odds ratio (OR) = 3.78; CI = 2.10–6.48; p = 1.16 × 10−5). This association remained significant in the hereditary breast cancer (HBC) group (OR = 4.18; CI = 2.10–7.70; p = 5.45 × 10−5). Furthermore, deleterious BARD1 variants were enriched among triple-negative BC patients (OR = 5.40; CI = 1.77–18.15; p = 0.001) compared to other BC subtypes. Our results support the role of BARD1 as a moderate penetrance BC predisposing gene and highlight a stronger association with triple-negative tumors., Contract grant sponsor: Supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—(PI19/00553; PI16/00563; PI16/01898; PI16/11363; PI15/00355; PI12/02585; SAF2015-68016-R and CIBERONC); the Government of Catalonia (Pla estratègic de recerca i innovació en salut (PERIS_MedPerCan and URDCat projects), 2017SGR1282 and 2017SGR496); and CERCA Programa/Generalitat de Catalunya for institutional support. GCAT is supported by Acción de Dinamización del ISCIII-MINECO (ADE 10/00026), by the Ministry of Health of the Generalitat of Catalunya and by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529) and GCAT Cession Research Project PI-2018-09 GCAT_CM.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?

  • Feliubadaló, Lídia
  • Grau Garces, Èlia
  • Velasco, Àngela
  • Balmaña Gelpí, Judith
  • Rofes, Paula
  • del Valle, Jesús
  • Stradella, Agostina
Síndromes de càncer; Panell genètic; Proves genètiques, Síndromes de cáncer; Panel de genes; Prueba genética, Cancer syndromes; Gene panel; Genetic testing, Importance Genetic testing of hereditary cancer using comprehensive gene panels can identify patients with more than one pathogenic mutation in high and/or moderate-risk-associated cancer genes. This phenomenon is known as multilocus inherited neoplasia alleles syndrome (MINAS), which has been potentially linked to more severe clinical manifestations. Objective To determine the prevalence and clinical features of MINAS in a large cohort of adult patients with hereditary cancer homogeneously tested with the same gene panel. Patients and methods A cohort of 1023 unrelated patients with suspicion of hereditary cancer was screened using a validated panel including up to 135 genes associated with hereditary cancer and phakomatoses. Results Thirteen (1.37%) patients harbouring two pathogenic mutations in dominant cancer-predisposing genes were identified, representing 5.7% (13/226) of patients with pathogenic mutations. Most (10/13) of these cases presented clinical manifestations associated with only one of the mutations identified. One case showed mutations in MEN1 and MLH1 and developed tumours associated with both cancer syndromes. Interestingly, three of the double mutants had a young age of onset or severe breast cancer phenotype and carried mutations in moderate to low-risk DNA damage repair-associated genes; two of them presented biallelic inactivation of CHEK2. We included these two patients for the sake of their clinical interest although we are aware that they do not exactly fulfil the definition of MINAS since both mutations are in the same gene. Conclusions and relevance Genetic analysis of a broad cancer gene panel identified the largest series of patients with MINAS described in a single study. Overall, our data do not support the existence of more severe manifestations in double mutants at the time of diagnosis although they do confirm previous evidence of severe phenotype in biallelic CHEK2 and other DNA repair cancer-predisposing genes., Contract grant sponsor: Supported by the Carlos III National Health Institute and Ministerio de Educación y Ciencia funded by FEDER funds–a way to build Europe (PI16/00563, PI16/01363, SAF2015-68016-R and CIBERONC); the Government of Catalonia (Pla estratègic de recerca i innovació en salut (PERIS), 2017SGR1282 and 2017SGR496); and the scientific foundation Asociación Española Contra el Cáncer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia

  • De Asis Tuazon, Anna Marie
  • Lott, Paul
  • Bohórquez, Mabel
  • Benavides, Jennyfer
  • Ramirez, Carolina
  • Criollo, Angel
  • Diez Gibert, Orland
Càncer de mama; Mutació fundadora; Haplotip, Cáncer de mama; Mutación fundadora; Haplotipo, Breast cancer; Founder mutation; Haplotype, Background The BRCA1 c.3331_3334delCAAG founder mutation has been reported in hereditary breast and ovarian cancer families from multiple Hispanic groups. We aimed to evaluate BRCA1 c.3331_3334delCAAG haplotype diversity in cases of European, African, and Latin American ancestry. Methods BC mutation carrier cases from Colombia (n = 32), Spain (n = 13), Portugal (n = 2), Chile (n = 10), Africa (n = 1), and Brazil (n = 2) were genotyped with the genome-wide single nucleotide polymorphism (SNP) arrays to evaluate haplotype diversity around BRCA1 c.3331_3334delCAAG. Additional Portuguese (n = 13) and Brazilian (n = 18) BC mutation carriers were genotyped for 15 informative SNPs surrounding BRCA1. Data were phased using SHAPEIT2, and identical by descent regions were determined using BEAGLE and GERMLINE. DMLE+ was used to date the mutation in Colombia and Iberia. Results The haplotype reconstruction revealed a shared 264.4-kb region among carriers from all six countries. The estimated mutation age was ~ 100 generations in Iberia and that it was introduced to South America early during the European colonization period. Conclusions Our results suggest that this mutation originated in Iberia and later introduced to Colombia and South America at the time of Spanish colonization during the early 1500s. We also found that the Colombian mutation carriers had higher European ancestry, at the BRCA1 gene harboring chromosome 17, than controls, which further supported the European origin of the mutation. Understanding founder mutations in diverse populations has implications in implementing cost-effective, ancestry-informed screening., AMDEA was supported with graduate Fellowships from UC Davis T32 Biotechnology Program. MB, ME, and LGC-C received funding from GSK Oncology and from “Oficina de Desarrollo a la Docencia de la Universidad del Tolima, Convocatoria 2010”. AC and AEF received funding from the Colciencias program “Becas Doctorales Nacionales, Convocatorias 528-2011 and 647-2015”. JB received funding from the Colciencias program “Formación de Capital Humano de Alto Nivel para el Departamento de Tolima- 2016, convocatoria 755”. BRCA1/2 genotyping of the Brazilian patients was performed in part with grants from CNPq (408313/2016-1), FAPERGS and Fundo de Incentivo a Pesquisa (FIPE) do Hospital de Clínicas de Porto Alegre, Brazil. AV received funding from CIBERER (grant ER17P1AC7112/2017). PC received funding from FONDEF grant #CA12I10152. CL was Supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI19/00553; PI16/00563; PI16/01898; SAF2015-68016-R and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS_MedPerCan and URDCat projects), 2017SGR1282 and 2017SGR496]. BR received funding from the National Institutes of Health (R01GM123306). The contents of this article are solely the responsibility of the authors and do not reflect the official views of the National Institutes of Health. LGC-C received from the V Foundation for Cancer Research and from The Auburn Community Cancer Endowed Chair in Basic Science.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez-Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune Cell Associations with Cancer Risk

  • Palomero, Luis|||0000-0002-9144-1017
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • de Cid, Rafael|||0000-0003-3579-6777
  • Espín, Roderic
  • Barnes, Daniel R.|||0000-0002-3781-7570
  • Blommaert, Eline
  • Gil-Gil, Miguel|||0000-0003-1380-2718
  • Falo, Catalina|||0000-0002-5714-6823
  • Stradella, Agostina|||0000-0002-2307-8869
  • Ouchi, Dan|||0000-0002-8630-152X
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • Violán, Concepció|||0000-0003-3309-5360
  • Peña-Chilet, María|||0000-0002-6445-9617
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Extremera, Ana Isabel
  • García-Valero, Mar
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Mateo, Francesca|||0000-0002-2342-7010
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Beesley, Jonathan
  • Chenevix-Trench, Georgia
  • Roux, Cecilia
  • Mak, Tak
  • Brunet, Joan|||0000-0003-1945-3512
  • Hakem, Razq
  • Gorrini, Chiara
  • Antoniou, Antonis C.
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in immune and/or stromal cell contents in the corresponding tissue. Predicted target genes show expression and regulatory associations with immune features. Polygenic risk scores also reveal associations with immune and/or stromal cell contents, and breast cancer scores show consistent results in normal and tumor tissue. SH2B3 links peripheral alterations of several immune cell types to the risk of this malignancy. Pleiotropic SH2B3 variants are associated with breast cancer risk in BRCA1/2 mutation carriers. A retrospective case-cohort study indicates a positive association between blood counts of basophils, leukocytes, and monocytes and age at breast cancer diagnosis. These findings broaden our knowledge of the role of the immune system in cancer and highlight promising prevention strategies for individuals at high risk. Immunology; Cancer Systems Biology; Cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT), initial results from an international prospective study

  • Bancroft, Elizabeth|||0000-0002-5482-5660
  • Page, Elizabeth C.
  • Brook, Mark N.|||0000-0002-8969-2378
  • Thomas, Sarah
  • Taylor, Natalie
  • Pope, Jennifer
  • McHugh, Jana
  • Jones, Ann-Britt
  • Karlsson, Questa
  • Merson, Susan
  • Ong, Kai Ren
  • Hoffman, Jonathan
  • Huber, Camilla
  • Maehle, Lovise
  • Grindedal, Eli Marie
  • Stormorken, Astrid
  • Evans, Gareth|||0000-0002-8482-5784
  • Rothwell, Jeanette
  • Lalloo, Fiona
  • Brady, Angela F.
  • Bartlett, Marion
  • Snape, Katie
  • Hanson, Helen
  • James, Paul|||0000-0002-4361-4657
  • McKinley, Joanne
  • Mascarenhas, Lyon
  • Syngal, Sapna
  • Ukaegbu, Chinedu
  • Side, Lucy
  • Thomas, Tessy
  • Barwell, Julian
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Izatt, Louise|||0000-0003-1258-4843
  • Suri, Mohnish|||0000-0001-9037-701X
  • Macrae, Finlay A.
  • Poplawski, Nicola
  • Chen-Shtoyerman, Rakefet|||0000-0002-5055-5907
  • Ahmed, Munaza
  • Musgrave, Hannah
  • Nicolai, Nicola|||0000-0002-5718-2699
  • Greenhalgh, Lynn
  • Brewer, Carole
  • Pachter, Nicholas
  • Spigelman, Allan D.
  • Azzabi, Ashraf
  • Helfand, Brian T.
  • Halliday, Dorothy
  • Buys, Saundra|||0000-0003-4120-5697
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Donaldson, Alan|||0000-0001-9193-4172
  • Cooney, Kathleen A.
  • Harris, Marion
  • McGrath, John
  • Davidson, Rosemarie
  • Taylor, Amy
  • Cooke, Peter
  • Myhill, Kathryn
  • Hogben, Matthew
  • Aaronson, Neil K.
  • Ardern-Jones, Audrey
  • Bangma, Chris H.
  • Castro, Elena|||0000-0002-3691-6454
  • Dearnaley, David|||0000-0002-3954-2806
  • Dias, Alexander
  • Dudderidge, Tim|||0000-0001-6373-3613
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Green, Kate
  • Eyfjord, Jorunn
  • Falconer, Alison
  • Foster, Christopher S.
  • Gronberg, Henrik
  • Hamdy, Freddie C.|||0000-0003-2627-2154
  • Johannsson, Oskar
  • Khoo, Vincent
  • Lilja, Hans|||0000-0001-5871-7846
  • Lindeman, Geoffrey J.|||0000-0001-9386-2416
  • Lubinski, Jan|||0000-0003-2931-3003
  • Axcrona, Karol|||0000-0002-5011-0107
  • Mikropoulos, Christos|||0000-0001-8070-2851
  • Mitra, Anita V.
  • Moynihan, Clare
  • Ni Raghallaigh, Holly
  • Rennert, Gad|||0000-0002-8512-068X
  • Collier, Rebecca
  • Offman, Judith|||0000-0001-5604-1635
  • Kote-Jarai, Zsofia|||0000-0002-6329-5155
  • Eeles, Rosalind|||0000-0002-3698-6241
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This study is registered with , , and is now closed to accrual. Between Sept 28, 2012, and March 1, 2020, 828 men were recruited (644 carriers of mismatch repair pathogenic variants [204 carriers of MLH1, 305 carriers of MSH2, and 135 carriers of MSH6 ] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6 ]), and in order to boost the sample size for the non-carrier control groups, we randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPACT study, who were included in all three non-carrier cohorts. Men were predominantly of European ancestry (899 [93%] of 953 with available data), with a mean age of 52·8 years (SD 8·3). Within the first screening round, 56 (6%) men had a PSA concentration of more than 3·0 ng/mL and 35 (4%) biopsies were done. The overall incidence of prostate cancer was 1·9% (18 of 962; 95% CI 1·1-2·9). The incidence among MSH2 carriers was 4·3% (13 of 305; 95% CI 2·3-7·2), MSH2 non-carrier controls was 0·5% (one of 210; 0·0-2·6), MSH6 carriers was 3·0% (four of 135; 0·8-7·4), and none were detected among the MLH1 carriers, MLH1 non-carrier controls, and MSH6 non-carrier controls. Prostate cancer incidence, using a PSA threshold of higher than 3·0 ng/mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4·3% vs 0·5%; p=0·011) and MSH6 carriers than MSH6 non-carrier controls (3·0% vs 0%; p=0·034). The overall positive predictive value of biopsy using a PSA threshold of 3·0 ng/mL was 51·4% (95% CI 34·0-68·6), and the overall positive predictive value of a PSA threshold of 3·0 ng/mL was 32·1% (20·3-46·0). After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer compared with age-matched non-carrier controls. These findings support the use of targeted PSA screening in these men to identify those with clinically significant prostate cancer. Further annual screening rounds will need to confirm these findings.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

  • Rofes, Paula|||0000-0001-6045-7879
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Torres Esquius, Sara|||0000-0001-7540-7284
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Stradella, Agostina|||0000-0002-2307-8869
  • Moreno-Cabrera, José Marcos|||0000-0001-8570-0345
  • López-Doriga, Adriana
  • Munté, Elisabet|||0000-0001-8396-8284
  • de Cid, Rafael|||0000-0003-3579-6777
  • Campos, Olga
  • Cuesta, Raquel
  • Teulé, Álex
  • Grau, Èlia
  • Sanz, Judit
  • Capella, Gabriel|||0000-0002-4669-7320
  • Diez, Orland|||0000-0001-7339-0570
  • Brunet, Joan|||0000-0003-1945-3512
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Lázaro García, Conxi|||0000-0002-7198-5906
Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1-associated ring domain 1 (BARD1), nuclear partner of BRCA1, has been suggested as a potential HBOC risk gene, although its prevalence and penetrance are variable according to populations and type of tumor. We aimed to investigate the prevalence of BARD1 truncating variants in a cohort of patients with clinical suspicion of HBOC. A comprehensive BARD1 screening by multigene panel analysis was performed in 4015 unrelated patients according to our regional guidelines for genetic testing in hereditary cancer. In addition, 51,202 Genome Aggregation Database (gnomAD) non-Finnish, non-cancer European individuals were used as a control population. In our patient cohort, we identified 19 patients with heterozygous BARD1 truncating variants (0.47%), whereas the frequency observed in the gnomAD controls was 0.12%. We found a statistically significant association of truncating BARD1 variants with overall risk (odds ratio (OR) = 3.78; CI = 2.10-6.48; p = 1.16 × 10 -5). This association remained significant in the hereditary breast cancer (HBC) group (OR = 4.18; CI = 2.10-7.70; p = 5.45 × 10 -5). Furthermore, deleterious BARD1 variants were enriched among triple-negative BC patients (OR = 5.40; CI = 1.77-18.15; p = 0.001) compared to other BC subtypes. Our results support the role of BARD1 as a moderate penetrance BC predisposing gene and highlight a stronger association with triple-negative tumors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra|||0000-0003-4931-1267
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Magraner-Pardo, Lorena
  • Vidal, August|||0000-0001-5727-2099
  • Pineda, Marta|||0000-0002-5403-5845
  • Cinnirella, Giacomo
  • Martín-Ramos, Edgar
  • Pons, Tirso|||0000-0002-7616-7750
  • López-Doriga, Adriana
  • Belhadj, Sami|||0000-0002-0528-9187
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Munoz-Torres, Pau M.|||0000-0002-0168-3224
  • Navarro, Matilde
  • Grau, Elia
  • Darder, Esther
  • Llort, Gemma|||0000-0001-9987-7862
  • Sanz, Judit
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Brunet, Joan|||0000-0003-1945-3512
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Sanz-Pamplona, Rebeca
  • Aligué, Rosa
  • Capella, Gabriel|||0000-0002-4669-7320
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Valle, Laura|||0000-0003-0371-0844
Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case-control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Polymerase proofreading-associated syndrome constitutes 0.1-0.4% of familial cancer cases, reaching 0.3-0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Interim Results from the IMPACT Study, Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

  • Page, Elizabeth C.
  • Bancroft, Elizabeth|||0000-0002-5482-5660
  • Brook, Mark N.|||0000-0002-8969-2378
  • Assel, Melissa
  • Hassan Al Battat, Mona
  • Thomas, Sarah
  • Taylor, Natalie
  • Chamberlain, Anthony
  • Pope, Jennifer
  • Raghallaigh, Holly Ni
  • Evans, Gareth|||0000-0002-8482-5784
  • Rothwell, Jeanette
  • Maehle, Lovise
  • Grindedal, Eli Marie
  • James, Paul|||0000-0002-4361-4657
  • Mascarenhas, Lyon
  • McKinley, Joanne
  • Side, Lucy
  • Thomas, Tessy
  • van Asperen, Christi
  • Vasen, Hans|||0000-0003-2682-2603
  • Kiemeney, Lambertus A.
  • Ringelberg, Janneke
  • Jensen, Thomas Dyrso
  • Osther, Palle Jörn Sloth|||0000-0001-7962-1640
  • Helfand, Brian T.
  • Genova, Elena
  • Oldenburg, Rogier A.
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Wokolorczyk, Dominika
  • Ong, Kai-Ren
  • Huber, Camilla
  • Lam, Jimmy
  • Taylor, Louise
  • Salinas, Monica
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Oosterwijk, Jan C.
  • van Zelst-Stams, Wendy
  • Cook, Jackie
  • Rosario, Derek J.|||0000-0002-9086-3592
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Powers, Jacquelyn
  • Buys, Saundra|||0000-0003-4120-5697
  • O'Toole, Karen
  • Ausems, Margreet G. E. M.
  • Schmutzler, Rita K.
  • Rhiem, Kerstin
  • Izatt, Louise|||0000-0003-1258-4843
  • Tripathi, Vishakha
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Cardoso, Marta|||0000-0002-3633-1659
  • Foulkes, William|||0000-0001-7427-4651
  • Aprikian, Armen
  • van Randeraad, Heleen
  • Davidson, Rosemarie
  • Longmuir, Mark
  • Ruijs, Marielle W.G.
  • Helderman van den Enden, Apollonia T.J.M.
  • Adank, Muriel A.
  • Williams, Rachel|||0000-0001-6353-944X
  • Andrews, Lesley
  • Murphy, Declan G.
  • Halliday, Dorothy
  • Walker, Lisa
  • Liljegren, Annelie
  • Carlsson, Stefan
  • Azzabi, Ashraf
  • Jobson, Irene
  • Morton, Catherine
  • Shackleton, Kylie
  • Snape, Katie
  • Hanson, Helen
  • Harris, Marion
  • Tischkowitz, Marc
  • Taylor, Amy
  • Kirk, Judy
  • Susman, Rachel
  • Chen-Shtoyerman, Rakefet|||0000-0002-5055-5907
  • Spigelman, Allan
  • Pachter, Nicholas
  • Ahmed, Munaza
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Zgajnar, Janez
  • Brewer, Carole
  • Gadea, Neus|||0000-0002-6736-3979
  • Brady, Angela F.
  • Van Os, Theo
  • Gallagher, David
  • Johannsson, Oskar
  • Donaldson, Alan|||0000-0001-9193-4172
  • Barwell, Julian
  • Nicolai, Nicola|||0000-0002-5718-2699
  • Friedman, Eitan|||0000-0002-6745-1733
  • Obeid, Elias|||0000-0001-5120-9435
  • Greenhalgh, Lynn
  • Murthy, Vedang|||0000-0001-6011-9319
  • Copakova, Lucia
  • Saya, Sibel|||0000-0002-4796-6852
  • McGrath, John
  • Cooke, Peter
  • Rønlund, Karina
  • Richardson, Kate
  • Henderson, Alex
  • Teo, Soo|||0000-0002-0444-590X
  • Arun, Banu K.
  • Kast, Karin|||0000-0001-6531-755X
  • Dias, Alexander
  • Aaronson, Neil K.
  • Ardern-Jones, Audrey
  • Bangma, Chris H.
  • Castro, Elena|||0000-0002-3691-6454
  • Dearnaley, David|||0000-0002-3954-2806
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Tricker, Karen
  • Eyfjord, Jorunn
  • Falconer, Alison
  • Foster, Christopher
  • Gronberg, Henrik
  • Hamdy, Freddie C.|||0000-0003-2627-2154
  • Stefansdottir, Vigdis|||0000-0003-4451-3126
  • Khoo, Vincent
  • Lindeman, Geoffrey J.|||0000-0001-9386-2416
  • Lubinski, Jan|||0000-0003-2931-3003
  • Axcrona, Karol|||0000-0002-5011-0107
  • Mikropoulos, Christos|||0000-0001-8070-2851
  • Mitra, Anita
  • Moynihan, Clare
  • Rennert, Gad|||0000-0002-8512-068X
  • Suri, Mohnish|||0000-0001-9037-701X
  • Wilson, Penny
  • Dudderidge, Tim|||0000-0001-6373-3613
  • Offman, Judith|||0000-0001-5604-1635
  • Kote-Jarai, Zsofia|||0000-0002-6329-5155
  • Vickers, Andrew J.|||0000-0003-1525-6503
  • Lilja, Hans|||0000-0001-5871-7846
  • Eeles, Rosalind|||0000-0002-3698-6241
Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Expanding a precision medicine platform for malignant peripheral nerve sheath tumors, New patient-derived orthotopic xenografts, cell lines and tumor entities

  • Creus-Bachiller, Edgar
  • Fernández-Rodríguez, Juana
  • Magallon-Lorenz, Miriam|||0000-0003-2741-4572
  • Ortega-Bertran, Sara
  • Navas-Rutete, Susana
  • Romagosa Perez Portabella, Maria Cleofe|||0000-0002-9478-7320
  • Silva, Tulio M.
  • Pané, Maria|||0000-0001-6107-2006
  • Estival, Anna|||0000-0002-2788-9159
  • Perez Sidelnikova, Diana
  • Morell, Mireia
  • Mazuelas, Helena
  • Carrió, Meritxell|||0000-0002-1258-6593
  • Lausová, Tereza
  • Reuss, Diana
  • Gel, Bernat|||0000-0001-8878-349X
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Serra, Eduard|||0000-0003-2895-9857
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas with a poor survival rate, presenting either sporadically or in the context of neurofibromatosis type 1 (NF1). The histological diagnosis of MPNSTs can be challenging, with different tumors exhibiting great histological and marker expression overlap. This heterogeneity could be partly responsible for the observed disparity in treatment response due to the inherent diversity of the preclinical models used. For several years, our group has been generating a large patient-derived orthotopic xenograft (PDOX) MPNST platform for identifying new precision medicine treatments. Herein, we describe the expansion of this platform using six primary tumors clinically diagnosed as MPNSTs, from which we obtained six additional PDOX mouse models and three cell lines, thus generating three pairs of in vitro-in vivo models. We extensively characterized these tumors and derived preclinical models, including genomic, epigenomic, and histological analyses. Tumors were reclassified after these analyses: three remained as MPNSTs (two being classic MPNSTs), one was a melanoma, another was a neurotrophic tyrosine receptor kinase (NTRK)-rearranged spindle cell neoplasm, and, finally, the last was an unclassifiable tumor bearing neurofibromin-2 (NF2) inactivation, a neuroblastoma RAS viral oncogene homolog (NRAS) oncogenic mutation, and a SWI/SNF-related matrix-associated actin-dependent regulator of chromatin (SMARCA4) heterozygous truncated variant. New cell lines and PDOXs faithfully recapitulated histology, marker expression, and genomic characteristics of the primary tumors. The diversity in tumor identity and their specific associated genomic alterations impacted treatment responses obtained when we used the new cell lines for testing compounds against known altered pathways in MPNSTs. In summary, we present here an extension of our MPNST precision medicine platform, with new PDOXs and cell lines, including tumor entities confounded as MPNSTs in a real clinical scenario. This platform may constitute a useful tool for obtaining correct preclinical information to guide MPNST clinical trials.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia

  • De Asis Tuazon, Anna Marie
  • Lott, Paul
  • Bohórquez, Mabel
  • Benavides, Jennyfer
  • Ramirez, Carolina
  • Criollo, Angel
  • Diez Gibert, Orland
Càncer de mama; Mutació fundadora; Haplotip, Cáncer de mama; Mutación fundadora; Haplotipo, Breast cancer; Founder mutation; Haplotype, Background The BRCA1 c.3331_3334delCAAG founder mutation has been reported in hereditary breast and ovarian cancer families from multiple Hispanic groups. We aimed to evaluate BRCA1 c.3331_3334delCAAG haplotype diversity in cases of European, African, and Latin American ancestry. Methods BC mutation carrier cases from Colombia (n = 32), Spain (n = 13), Portugal (n = 2), Chile (n = 10), Africa (n = 1), and Brazil (n = 2) were genotyped with the genome-wide single nucleotide polymorphism (SNP) arrays to evaluate haplotype diversity around BRCA1 c.3331_3334delCAAG. Additional Portuguese (n = 13) and Brazilian (n = 18) BC mutation carriers were genotyped for 15 informative SNPs surrounding BRCA1. Data were phased using SHAPEIT2, and identical by descent regions were determined using BEAGLE and GERMLINE. DMLE+ was used to date the mutation in Colombia and Iberia. Results The haplotype reconstruction revealed a shared 264.4-kb region among carriers from all six countries. The estimated mutation age was ~ 100 generations in Iberia and that it was introduced to South America early during the European colonization period. Conclusions Our results suggest that this mutation originated in Iberia and later introduced to Colombia and South America at the time of Spanish colonization during the early 1500s. We also found that the Colombian mutation carriers had higher European ancestry, at the BRCA1 gene harboring chromosome 17, than controls, which further supported the European origin of the mutation. Understanding founder mutations in diverse populations has implications in implementing cost-effective, ancestry-informed screening., AMDEA was supported with graduate Fellowships from UC Davis T32 Biotechnology Program. MB, ME, and LGC-C received funding from GSK Oncology and from “Oficina de Desarrollo a la Docencia de la Universidad del Tolima, Convocatoria 2010”. AC and AEF received funding from the Colciencias program “Becas Doctorales Nacionales, Convocatorias 528-2011 and 647-2015”. JB received funding from the Colciencias program “Formación de Capital Humano de Alto Nivel para el Departamento de Tolima- 2016, convocatoria 755”. BRCA1/2 genotyping of the Brazilian patients was performed in part with grants from CNPq (408313/2016-1), FAPERGS and Fundo de Incentivo a Pesquisa (FIPE) do Hospital de Clínicas de Porto Alegre, Brazil. AV received funding from CIBERER (grant ER17P1AC7112/2017). PC received funding from FONDEF grant #CA12I10152. CL was Supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI19/00553; PI16/00563; PI16/01898; SAF2015-68016-R and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS_MedPerCan and URDCat projects), 2017SGR1282 and 2017SGR496]. BR received funding from the National Institutes of Health (R01GM123306). The contents of this article are solely the responsibility of the authors and do not reflect the official views of the National Institutes of Health. LGC-C received from the V Foundation for Cancer Research and from The Auburn Community Cancer Endowed Chair in Basic Science.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

  • Torres Esquius, Sara
  • Feliubadaló, Lídia
  • Moreno-Cabrera, José Marcos
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Rofes, Paula
  • del Valle, Jesús
  • Stradella, Agostina
BARD1; Càncer hereditari de mama i ovari; Risc moderat de càncer, BARD1; Cáncer de mama y ovario hereditario; Riesgo de cáncer moderado, BARD1; Hereditary breast and ovarian cancer; Moderate cancer risk, Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1-associated ring domain 1 (BARD1), nuclear partner of BRCA1, has been suggested as a potential HBOC risk gene, although its prevalence and penetrance are variable according to populations and type of tumor. We aimed to investigate the prevalence of BARD1 truncating variants in a cohort of patients with clinical suspicion of HBOC. A comprehensive BARD1 screening by multigene panel analysis was performed in 4015 unrelated patients according to our regional guidelines for genetic testing in hereditary cancer. In addition, 51,202 Genome Aggregation Database (gnomAD) non-Finnish, non-cancer European individuals were used as a control population. In our patient cohort, we identified 19 patients with heterozygous BARD1 truncating variants (0.47%), whereas the frequency observed in the gnomAD controls was 0.12%. We found a statistically significant association of truncating BARD1 variants with overall risk (odds ratio (OR) = 3.78; CI = 2.10–6.48; p = 1.16 × 10−5). This association remained significant in the hereditary breast cancer (HBC) group (OR = 4.18; CI = 2.10–7.70; p = 5.45 × 10−5). Furthermore, deleterious BARD1 variants were enriched among triple-negative BC patients (OR = 5.40; CI = 1.77–18.15; p = 0.001) compared to other BC subtypes. Our results support the role of BARD1 as a moderate penetrance BC predisposing gene and highlight a stronger association with triple-negative tumors., Contract grant sponsor: Supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—(PI19/00553; PI16/00563; PI16/01898; PI16/11363; PI15/00355; PI12/02585; SAF2015-68016-R and CIBERONC); the Government of Catalonia (Pla estratègic de recerca i innovació en salut (PERIS_MedPerCan and URDCat projects), 2017SGR1282 and 2017SGR496); and CERCA Programa/Generalitat de Catalunya for institutional support. GCAT is supported by Acción de Dinamización del ISCIII-MINECO (ADE 10/00026), by the Ministry of Health of the Generalitat of Catalunya and by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529) and GCAT Cession Research Project PI-2018-09 GCAT_CM.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?

  • Feliubadaló, Lídia
  • Grau Garces, Èlia
  • Velasco, Àngela
  • Balmaña Gelpí, Judith
  • Rofes, Paula
  • del Valle, Jesús
  • Stradella, Agostina
Síndromes de càncer; Panell genètic; Proves genètiques, Síndromes de cáncer; Panel de genes; Prueba genética, Cancer syndromes; Gene panel; Genetic testing, Importance Genetic testing of hereditary cancer using comprehensive gene panels can identify patients with more than one pathogenic mutation in high and/or moderate-risk-associated cancer genes. This phenomenon is known as multilocus inherited neoplasia alleles syndrome (MINAS), which has been potentially linked to more severe clinical manifestations. Objective To determine the prevalence and clinical features of MINAS in a large cohort of adult patients with hereditary cancer homogeneously tested with the same gene panel. Patients and methods A cohort of 1023 unrelated patients with suspicion of hereditary cancer was screened using a validated panel including up to 135 genes associated with hereditary cancer and phakomatoses. Results Thirteen (1.37%) patients harbouring two pathogenic mutations in dominant cancer-predisposing genes were identified, representing 5.7% (13/226) of patients with pathogenic mutations. Most (10/13) of these cases presented clinical manifestations associated with only one of the mutations identified. One case showed mutations in MEN1 and MLH1 and developed tumours associated with both cancer syndromes. Interestingly, three of the double mutants had a young age of onset or severe breast cancer phenotype and carried mutations in moderate to low-risk DNA damage repair-associated genes; two of them presented biallelic inactivation of CHEK2. We included these two patients for the sake of their clinical interest although we are aware that they do not exactly fulfil the definition of MINAS since both mutations are in the same gene. Conclusions and relevance Genetic analysis of a broad cancer gene panel identified the largest series of patients with MINAS described in a single study. Overall, our data do not support the existence of more severe manifestations in double mutants at the time of diagnosis although they do confirm previous evidence of severe phenotype in biallelic CHEK2 and other DNA repair cancer-predisposing genes., Contract grant sponsor: Supported by the Carlos III National Health Institute and Ministerio de Educación y Ciencia funded by FEDER funds–a way to build Europe (PI16/00563, PI16/01363, SAF2015-68016-R and CIBERONC); the Government of Catalonia (Pla estratègic de recerca i innovació en salut (PERIS), 2017SGR1282 and 2017SGR496); and the scientific foundation Asociación Española Contra el Cáncer.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Role of POLE and POLD1 in familial cancer

  • Mur, Pilar
  • García-Mulero, Sandra
  • Vidal, August
  • Balmaña Gelpí, Judith
  • Pineda, Marta
  • del Valle, Jesús
  • Magraner-Pardo, Lorena
Domini de l'exonucleasa; Càncer colorectal hereditari; Fenotip ultramutat, Dominio exonucleasa; Cáncer colorrectal hereditario; Fenotipo ultramutado, Exonuclease domain; Hereditary colorectal cancer; Ultramutated phenotype, Purpose Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. The tumor spectrum and prevalence of POLE and POLD1 variants in hereditary cancer are evaluated in this study. Methods POLE and POLD1 were sequenced in 2813 unrelated probands referred for genetic counseling (2309 hereditary cancer patients subjected to a multigene panel, and 504 patients selected based on phenotypic characteristics). Cosegregation and case–control studies, yeast-based functional assays, and tumor mutational analyses were performed for variant interpretation. Results Twelve ED missense variants, 6 loss-of-function, and 23 outside-ED predicted-deleterious missense variants, all with population allele frequencies <1%, were identified. One ED variant (POLE p.Met294Arg) was classified as likely pathogenic, four as likely benign, and seven as variants of unknown significance. The most commonly associated tumor types were colorectal, endometrial and ovarian cancers. Loss-of-function and outside-ED variants are likely not pathogenic for this syndrome. Conclusions Polymerase proofreading–associated syndrome constitutes 0.1–0.4% of familial cancer cases, reaching 0.3–0.7% when only CRC and polyposis are considered. ED variant interpretation is challenging and should include multiple pieces of evidence., We thank Gemma Aiza, Mireia Menéndez, Sara González, and Xavier Muñoz for support, and Biobanc HUB-ICO-IDIBELL, integrated in the Spanish Platform Biobanks Network and funded by Instituto de Salud Carlos III (PT17/0015/0024) and Xarxa Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya. This work was funded by the Spanish Ministry of Science and Innovation, cofunded by FEDER funds (SAF2016-80888-R, SAF2015-68016-R, Severo Ochoa SVP-2014-068895 contract [L.M.-P.]); Instituto de Salud Carlos III (PI16/00563, PI16/00588, PI14/00613, PI19/00553, CIBERONC CB16/12/00234, CIBERESP, Sara Borrell contract [P.M.]); Government of Catalonia [AGAUR 2017SGR1282, CERCA Program]; and Fundación Olga Torres. This study was facilitated by COST Action CA17118, supported by COST (European Cooperation in Science and Technology).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Figlioli, Gisella
  • Kvist, Anders
  • Tham, Emma
  • Soukupova, Jana
  • Kleiblova, Petra
  • Muranen, Taru A
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
Predisposició al càncer de mama; Factors de risc de càncer de mama; Espectre de mutació, Predisposición al cáncer de mama; Factores de riesgo de cáncer de mama; Espectro de mutación, Breast cancer predisposition; Breast cancer risk factors; Mutation spectrum, Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2–4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases., This research was partially funded by Associazione Italiana Ricerca sul Cancro (AIRC; IG2015 no.16732) to P. Peterlongo, a fellowship from Fondazione Umberto Veronesi to G. Figlioli and by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds. E. Tham is supported by Region Stockholm (ALF). The Czech study was supported by a grant of the Ministry of Health of the Czech Republic NV16-29959A. CNIO study was partially supported by projects PI16/00440 and PI19/00640, supported by the Instituto de Salud Carlos III, cofunded by European Regional Development Fund (ERDF), the Spanish Network on Rare Diseases (CIBERER) and BRIDGES project H2020. Financial support for GENESIS resource and genotyping was provided by the Ligue Nationale contre le Cancer (grants PRE05/DSL, PRE07/DSL, PRE11/NA), the French National Institute of Cancer (INCa grant No b2008-029/LL-LC) and the comprehensive cancer center SiRIC, (Site de Recherche Intégrée sur le Cancer: Grant INCa-DGOS-4654). HEBCS was funded by Helsinki University Hospital Research Fund, Sigrid Juselius Foundation, The cancer Society of Finland. A.Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII) through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, INT17/00133), and through Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018). This work was supported by the Australian National Health and Medical Research Council (APP1029974 and APP1074383) and by a Victorian Life Sciences Computation Initiative grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government. T.N-D is a Career Development Fellow of the National Breast Cancer Foundation (Australia, ECF-17-001). M.C.S. is a National Health and Medical Research Council (Australia) Senior Research Fellow. The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 to E. Olah. Lithuanian study was supported by The Research Council of Lithuania grant SEN18/2015 and P-MIP-20-25 to R. Janavicius. The ICO was supported by the Carlos III National Health Institute funded by FEDER funds—a way to build Europe—[PI16/00563, PI19/00553 and CIBERONC]; the Government of Catalonia [Pla estratègic de recerca i innovació en salut (PERIS) Project MedPerCan, 2017SGR1282 and 2017SGR496]; and CERCA program.